Abstract
Frank Cobelens and colleagues outline key research questions that need to be addressed to maximize the impact of programmatic management of drug-resistant tuberculosis.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antitubercular Agents / therapeutic use*
-
Global Health
-
Humans
-
Research
-
Tuberculosis, Multidrug-Resistant / drug therapy
-
Tuberculosis, Multidrug-Resistant / prevention & control
-
Tuberculosis, Multidrug-Resistant / therapy*